Highlights

  • Zelira Therapeutics (ASX:ZLD) remains suspended from Quotation following a reporting compliance issue.
  • The company faces a separate listing fee deadline that could affect its ASX status.
  • Financial challenges include limited cash reserves, ongoing funding requirements and going-concern uncertainty.
  • Investors are monitoring reporting obligations, funding outcomes and potential reinstatement.

Zelira Therapeutics (ASX:ZLD), a medicinal cannabis developer focused on cannabinoid-based therapies, remains suspended from quotation on the Australian Securities Exchange as at 24 August 2026. The company is facing a critical compliance period as it works through outstanding reporting requirements and a separate listing-related deadline.

The existing suspension and the potential listing removal risk are separate matters. Zelira’s suspension was triggered by a failure to lodge a periodic report within the required timeframe, while the listing fee issue represents an additional compliance challenge that could affect the company’s future ASX status.

Key Development

Zelira Therapeutics entered suspension on 2 March 2026 under ASX Listing Rule 17.5 after failing to lodge a periodic financial report by the required deadline.

The company’s securities have remained suspended since then, with no confirmed reinstatement date available as at the research cut-off.

Alongside the existing suspension, the company faces an outstanding annual listing fee deadline. Failure to address the requirement could result in removal from the ASX Official List.

The fee-related issue is separate from the original suspension reason. The current suspension relates to reporting obligations, while the listing fee deadline represents another compliance matter that may influence the company’s future listing status.

There is no confirmed public information indicating that Zelira has entered administration, receivership or liquidation. The company’s current position reflects compliance and funding challenges rather than a confirmed Insolvency event.

Financial Position

Zelira’s latest available financial information highlights the financial pressures facing the business.

In its FY2025 Annual Report, the company reported cash and cash equivalents of approximately $5,663 at 30 June 2025, compared with $586,161 in the previous year.

Operating revenue declined significantly to $656 in FY2025 from $94,952 in FY2024, reflecting limited commercial activity during the period.

The company reported a net loss after tax of approximately $3.85 million, compared with a larger loss in the previous year. The prior-year result included a significant Goodwill impairment, affecting the comparison between periods.

The Balance Sheet included current convertible notes and Lease liabilities, contributing to total current liabilities of approximately $5.59 million.

During FY2025, Zelira converted approximately US$3.25 million of convertible notes into Equity and continued restructuring its Capital position.

The company’s financial statements also highlighted material uncertainty regarding its ability to continue as a going concern, with future operations dependent on additional funding and progress across its clinical and commercial programs.

Management View

Zelira’s previous communications have focused on its medicinal cannabis pipeline and product development activities.

The company has highlighted its HOPE formulations, targeting areas including autism and pain management, along with regulatory progress and intellectual property developments.

Zelira has also promoted ZENIVOL, a cannabinoid-based treatment targeting chronic insomnia, as well as research activities related to its broader therapeutic pipeline.

Regarding the suspension, the company’s position has centred on resolving reporting requirements and meeting ASX compliance obligations. However, no confirmed reinstatement timeline had been announced as at the research cut-off.

Investor Focus

With trading suspended, investors do not have an active Market Price to assess changes in company value.

A prolonged suspension reduces Liquidity and limits shareholders’ ability to buy or sell securities through the ASX.

The immediate focus is on whether Zelira can satisfy outstanding compliance requirements, maintain its listing status and secure the funding required to continue operations.

The company’s limited cash position and need for additional capital remain central issues for investors assessing the company’s future.

Future Catalysts

The most immediate catalysts are administrative and financial.

Payment of outstanding listing-related obligations and completion of overdue reporting requirements would be important steps towards maintaining the company’s ASX status.

Further funding support, strategic partnerships or progress in commercialising the company’s therapeutic programs could also influence the company’s outlook.

However, until compliance matters are resolved and a reinstatement pathway is confirmed, uncertainty remains around the company’s listed status.

Key Risks

Zelira faces several significant risks, including limited cash reserves, ongoing funding requirements and uncertainty around its ability to continue as a going concern.

A failure to satisfy ASX requirements could result in further suspension or removal from the Official List.

Any future capital raising may result in substantial dilution for existing shareholders, particularly given the company’s previous use of convertible securities.

The medicinal cannabis sector also remains exposed to regulatory requirements, funding challenges and competitive pressures across global markets.

While the company faces financial and compliance challenges, there is no confirmed evidence of insolvency or administration.

Investor Takeaway

Zelira Therapeutics (ASX:ZLD) remains suspended from quotation while it works through reporting obligations and a separate listing compliance issue.

The key distinction for investors is that the existing suspension resulted from a missed periodic report, while the listing fee matter represents an additional risk to the company’s ASX status.

The immediate watch points are whether Zelira resolves outstanding compliance matters, secures additional funding and establishes a pathway towards reinstatement. Until then, shareholders remain exposed to significant uncertainty around liquidity, funding and the company’s future on the exchange.